Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters

Cancer Immunology, Immunotherapy

Volumn 61, Issue 11, 2012, Pages 2003-2011

  Aarntzen, Erik H J G ^a,b   De Vries, I Jolanda M ^a,b   GöErtz, Joop H ^a   Beldhuis Valkis, Marjo ^a   Brouwers, Huberdina M L M ^a   Van De Rakt, Mandy W M M ^b   Van Der Molen, Renate G ^a   Punt, Cornelis J A ^c   Adema, Gosse J ^b   Tacken, Paul J ^b   Joosten, Irma ^a   Jacobs, Joannes F M ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Adjuvant; Dendritic cell; Humoral response; Immunocompetence; Keyhole limpet hemocyanin; Vaccine

Indexed keywords

DENDRITIC CELL VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KEYHOLE LIMPET HEMOCYANIN; KEYHOLE LIMPET HEMOCYANIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ACCURACY; ANTIBODY RESPONSE; ARTICLE; CALIBRATION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; DENDRITIC CELL; DENDRITIC CELL BASED IMMUNOTHERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN PRODUCTION; IN VIVO STUDY; MAJOR CLINICAL STUDY; METASTATIC MELANOMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES; CANCER VACCINES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOCYANIN; HUMANS; IMMUNITY, HUMORAL; IMMUNOTHERAPY; MALE; MELANOMA; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 84870995896     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1263-z     Document Type: Article

References (40)

1. Harris JR, Markl J (1999) Keyhole limpet hemocyanin (KLH): A biomedical review. Micron 30(6):597-623
2. Swanson MA, Schwartz RS (1967) Immunosuppressive therapy. The relation between clinical response and immunologic competence. N Engl J Med 277(4):163-170
3. Perabo FG, Muller SC (2004) Current and new strategies in immunotherapy for superficial bladder cancer. Urology 64(3): 409-421
4. Schumacher K (2001) Keyhole limpet hemocyanin (KLH) conjugate vaccines as novel therapeutic tools in malignant disorders. J Cancer Res Clin Oncol 127(Suppl 2):R1-R2
5. Krug LM, Ragupathi G, Hood C, George C, Hong F, Shen R, Abrey L, Jennings HJ, Kris MG, Livingston PO (2012) Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci. Cancer Immunol Immunother 61(1):9-18
6. Gandhi RT, O'Neill D, Bosch RJ, Chan ES, Bucy RP, Shopis J, Baglyos L, Adams E, Fox L, Purdue L, Marshak A, Flynn T, Masih R, Schock B, Mildvan D, Schlesinger SJ, Marovich MA, Bhardwaj N, Jacobson JM (2009) A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells versus canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine 27(43):6088-6094
7. Melief CJ (2008) Cancer immunotherapy by dendritic cells. Immunity 29(3):372-383
8. Leonhartsberger N, Ramoner R, Putz T, Gander H, Rahm A, Falkensammer C, Bartsch G, Thurnher M (2007) Antigen-independent immune responses after dendritic cell vaccination. Cancer Immunol Immunother 56(6):897-903
9. Scheibenbogen C, Schadendorf D, Bechrakis NE, Nagorsen D, Hofmann U, Servetopoulou F, Letsch A, Philipp A, Foerster MH, Schmittel A, Thiel E, Keilholz U (2003) Effects of granulocytemacrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int J Cancer 104(2):188-194
10. Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK, Pawelec G, Hoerr I, Rammensee HG, Garbe C (2009) Direct injection of protamine-protected mRNA: Results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother 32(5):498-507
11. Verdijk P, Aarntzen EH, Lesterhuis WJ, Boullart AC, Kok E, van Rossum MM, Strijk S, Eijckeler F, Bonenkamp JJ, Jacobs JF, Blokx W, Vankrieken JH, Joosten I, Boerman OC, Oyen WJ, Adema G, Punt CJ, Figdor CG, De Vries IJ (2009) Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 15(7):2531-2540
12. Figdor CG, De Vries IJ, Lesterhuis WJ, Melief CJ (2004) Dendritic cell immunotherapy: Mapping the way. Nat Med 10(5): 475-480
13. De Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG, Punt CJ (2003) Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 9(14):5091-5100
14. Jacobs JF, Punt CJ, Lesterhuis WJ, Sutmuller RP, Brouwer HM, Scharenborg NM, Klasen IS, Hilbrands LB, Figdor CG, De Vries IJ, Adema GJ (2010) Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment, a phase I/II study in metastatic melanoma patients. Clin Cancer Res 16(20): 5067-5078
15. Lesterhuis WJ, De Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Croockewit S, van Rossum MM, Mus R, Oyen WJ, Boerman OC, Lucas S, Adema GJ, Punt CJ, Figdor CG (2011) Route of administration modulates the induction of dendritic cell vaccineinduced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res 17(17):5725-5735
16. De Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, Oyen WJ, Bonenkamp JJ, Boezeman JB, Adema GJ, Bulte JW, Scheenen TW, Punt CJ, Heerschap A, Figdor CG (2005) Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 23(11):1407-1413
17. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM (2009) Review of clinical studies on dendritic cellbased vaccination of patients with malignant melanoma: Assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 58(1):1-14
18. Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, Gullestad HP, Ryder T, Lislerud K, Hammerstad H, Gaudernack G (2006) Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 13(10):905-918
19. Kyte JA, Kvalheim G, Lislerud K, thor Straten P, Dueland S, Aamdal S, Gaudernack G (2007) T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. Cancer Immunol Immunother 56(5):659-675
20. Germeau C, Ma W, Schiavetti F, Lurquin C, Henry E, Vigneron N, Brasseur F, Lethe B, De Plaen E, Velu T, Boon T, Coulie PG (2005) High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 201(2):241-248
21. De Vries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJ, Ruiter DJ, Figdor CG, Punt CJ, Adema GJ (2005) Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 23(24): 5779-5787
22. Lopez MN, Pereda C, Segal G, Munoz L, Aguilera R, Gonzalez FE, Escobar A, Ginesta A, Reyes D, Gonzalez R, Mendoza-Naranjo A, Larrondo M, Compan A, Ferrada C, Salazar-Onfray F (2009) Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor betaexpressing T cells. J Clin Oncol 27(6):945-952
23. Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Pawelec G, Roep BO, Romero P, Hoos A, Davis MM (2011) Minimal information about T cell assays: The process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother 60(1):15-22
24. Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, Kast WM, Hoos A (2008) Results and harmonization guidelines from two largescale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 57(3):303-315
25. Neelapu SS, Baskar S, Kwak LW (2001) Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine. J Cancer Res Clin Oncol 127(Suppl 2):R14-R19
26. Spazierer D, Skvara H, Dawid M, Fallahi N, Gruber K, Rose K, Lloyd P, Heuerding S, Stingl G, Jung T (2009) T helper 2 biased de novo immune response to Keyhole Limpet Hemocyanin in humans. Clin Exp Allergy 39(7):999-1008
27. Kelly BS, Levy JG, Sikora L (1979) The use of the enzymelinked immunosorbent assay (ELISA) for the detection and quantification of specific antibody from cell cultures. Immunology 37(1):45-52
28. Korver K, Zeijlemaker WP, Schellekens PT, Vossen JM (1984) Measurement of primary in vivo IgM-and IgG-antibody response to KLH in humans: Implications of pre-immune IgM binding in antigen-specific ELISA. J Immunol Methods 74(2):241-251
29. Oyelaran O, Gildersleeve JC (2010) Evaluation of human antibody responses to keyhole limpet hemocyanin on a carbohydrate microarray. Proteom Clin Appl 4(3):285-294
30. Lesterhuis WJ, De Vries IJ, Schuurhuis DH, Boullart AC, Jacobs JF, de Boer AJ, Scharenborg NM, Brouwer HM, van de Rakt MW, Figdor CG, Ruers TJ, Adema GJ, Punt CJ (2006) Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: Antigen-specific T cell responses in DTH skin tests. Ann Oncol 17(6):974-980
31. Lesterhuis WJ, Schreibelt G, Scharenborg NM, Brouwer HM, Gerritsen MJ, Croockewit S, Coulie PG, Torensma R, Adema GJ, Figdor CG, De Vries IJ, Punt CJ (2011) Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responsesindependent of the peptide used. Cancer Immunol Immunother 60(2):249-260
32. Lane HC, Volkman DJ, Whalen G, Fauci AS (1981) In vitro antigen-induced, antigen-specific antibody production in man. Specific and polyclonal components, kinetics, and cellular requirements. J Exp Med 154(4):1043-1057
33. Stavnezer J (1996) Immunoglobulin class switching. Curr Opin Immunol 8(2):199-205
34. Waldmann TA (2007) Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: A 25-year personal odyssey. J Clin Immunol 27(1):1-18
35. Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, Harlin H (2006) Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 213:131-145
36. Whiteside TL (2010) Inhibiting the inhibitors: Evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther 10(7):1019-1035
37. Munn DH, Mellor AL (2007) Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117(5):1147-1154
38. Golub SH, Rangel DM, Morton DL (1977) In vitro assessment of immunocompetence in patients with malignant melanoma. Int J Cancer 20(6):873-880
39. Grant RW, Mariani RA, Vieira VJ, Fleshner M, Smith TP, Keylock KT, Lowder TW, McAuley E, Hu L, Chapman-Novakofski K, Woods JA (2008) Cardiovascular exercise intervention improves the primary antibody response to keyhole limpet hemocyanin (KLH) in previously sedentary older adults. Brain Behav Immun 22(6):923-932
40. Jurincic-Winkler CD, von der Kammer H, Beuth J, Scheit KH, Klippel KF (1996) Antibody response to keyhole limpet hemocyanin (KLH) treatment in patients with superficial bladder carcinoma. Anticancer Res 16(4A):2105-2110